Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.
Cartesian Therapeutics Inc. (RNAC) is a clinical-stage biopharmaceutical company pioneering mRNA cell therapies for autoimmune diseases through its proprietary ImmTOR platform. This page aggregates official press releases, clinical trial milestones, and strategic developments critical for understanding the company's progress in immunotherapy innovation.
Investors and researchers will find curated updates on RNAC's therapeutic pipeline, regulatory filings, and scientific advancements. Content spans trial results, partnership announcements, and financial disclosures—all essential for evaluating the company's position in the competitive cell therapy landscape.
Bookmark this page for direct access to Cartesian Therapeutics' verified news, ensuring you stay informed about their novel approach to modulating immune responses without genomic integration. Regular updates provide insights into how RNAC's mRNA technology addresses complex autoimmune conditions through transient, precision-engineered therapies.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) granted inducement awards to four new employees by issuing options to purchase shares of the Company's common stock. The options have an exercise price of $22.64 and are exercisable for a total of 72,769 shares. Each option vests over time and has a ten-year term. The grants were made under the Company's 2018 Employment Inducement Incentive Award Plan and were approved by the board of directors.
FAQ
What is the current stock price of Cartesian (RNAC)?
What is the market cap of Cartesian (RNAC)?
